Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adefovir and TACE in HBV-related HCC
NCT00960518Phase 2Unknown
- Sponsor
- Tongji University
- Start
- Aug 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adefovir dipivoxil in hepatocellular carcinoma (HCC), sponsored by Tongji University. Primary endpoint: Progression-Free Survival at 3 months. Status: unknown.
02
Drugs
adefovir dipivoxil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00960518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00960518.